Beneficial effects of amenorrhea from Dienogest on uterine leiomyomas in low- resource countries.

Beneficial effects of amenorrhea from Dienogest on uterine leiomyomas in low- resource countries.A Prospective clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202505682460357

Enrollment

Registered

2025-05-28

Start date

2023-09-03

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecology

Interventions

Deinogest

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1- Age 20-45 years. 2- Women diagnosed with uterine leiomyomas through transvaginal sonography.

Exclusion criteria

Exclusion criteria: 1-Pregnant women. 2- menopausal women. 3- women with a history of malignancies.

Design outcomes

Primary

Measure	Time frame
Leiomyoma volume: The Size of the myoma will be measured at three diameters of myomas (transverse, vertical, and anterior-posterior). The same sonographer will repeat these measurements after 3 months of therapy.	—

Secondary

Measure	Time frame
Actual blood loss per menstrual period, according to the pictorial blood loss assessment chart (PBLAC),	—

Countries

Egypt

Contacts

Public Contactahmed abdel hamid

Professor

ahmedgyna@yahoo.com00201227960980

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026